Key result
Pre-procedural frailty linked to ~2.1-fold higher post-LAAO mortality per 1-point CFS increase.
Why the study?
In older adults undergoing LAAO for either prohibitive bleeding risk or breakthrough thromboembolism on OAC, frailty may provide prognostic information not captured by chronological age or conventional risk scores.
Is pre-procedural frailty assessed by the Rockwood Clinical Frailty Scale associated with all-cause mortality and adverse clinical outcomes after percutaneous left atrial appendage occlusion across breakthrough-stroke and hemorrhagic indications in older adults?
Cohort (n=76)
No
Is pre-procedural frailty assessed by the Rockwood Clinical Frailty Scale associated with all-cause mortality and adverse clinical outcomes after percutaneous left atrial appendage occlusion across breakthrough-stroke and hemorrhagic indications in older adults?
In older adults undergoing percutaneous LAAO across breakthrough-stroke and bleeding-risk indications, pre-procedural frailty measured by the Rockwood CFS predicted post-procedural mortality better than chronological age, while hybrid LAAO plus continued OAC yielded zero recurrent thromboembolic events in breakthrough-stroke patients.
Answers are grounded in this paper and cite their sources.
May inform pre-LAAO frailty risk stratification in older adults; leaves open whether targeted interventions improve survival in prospective studies.
Background: Left atrial appendage occlusion (LAAO) is an established alternative to long-term oral anticoagulation in patients with prohibitive bleeding risk. It may also represent an adjunctive strategy in selected patients who experience thromboembolic events despite adequately managed anticoagulant therapy. This dual indication is particularly relevant in older adults, in whom frailty may provide prognostic information not captured by chronological age or conventional thromboembolic and bleeding scores. We therefore evaluated the prognostic relevance of pre-procedural frailty and clinical indication in a real-world LAAO cohort. Methods: We retrospectively analyzed 76 consecutive patients undergoing percutaneous LAAO: 43 with breakthrough ischemic stroke/TIA despite documented guideline-concordant OAC with no documented interruption or non-adherence and 33 with non-suitability for long-term OAC for prohibitive bleeding risk. Frailty was assessed using the Rockwood Clinical Frailty Scale (CFS), analyzed as an ordinal score and categorized as CFS 1– 3, CFS 4, or CFS ≥ 5. Results: Median age was 78 years (IQR 71– 82); median CFS was 3 (IQR 2– 4), and CFS ≥ 5 was present in 17/76 patients (22.4%). Procedural success was 100%, with no recorded major periprocedural complications. Follow-up was available in 72 patients (median 470 days, IQR 334– 578). No ischemic stroke/TIA/systemic embolism occurred in either group. Major bleeding occurred in 1/72 patients, DRT in 2/48 patients with imaging follow-up, and all-cause death in 10/72. OAC-based maintenance therapy was used in 38/39 breakthrough-stroke patients (97.4%) but in none of the 33 standard-indication patients, whereas 31/33 standard-indication patients (93.9%) received antiplatelet-only maintenance therapy. Conclusions: In this real-world LAAO cohort, CFS was associated with adverse outcomes and may provide prognostic information beyond chronological age. The absence of recurrent thromboembolic events should be interpreted according to indication: in breakthrough-stroke patients it occurred within a combined LAAO-plus-OAC strategy, whereas no ischemic events were observed in the standard cohort after OAC withdrawal. Given the limited event count, follow-up duration, and absence of a control group, these observations should be considered hypothesis-generating.
No takes yet. Share an insight, caveat, or question.
Castelli et al. (2026) conducted a cohort in Non-valvular atrial fibrillation undergoing percutaneous left atrial appendage occlusion (LAAO) (n=76). Pre-procedural frailty (Rockwood Clinical Frailty Scale [CFS] ≥5 vs CFS <5, and per 1-point increase) across LAAO indications vs. Lower frailty (CFS <5 / CFS 1-3) and breakthrough-stroke vs standard bleeding-risk LAAO indication was evaluated on All-cause death (HR 2.10 per 1-point CFS increase, 95% CI 1.19-3.71, p=0.011). Pre-procedural Rockwood Clinical Frailty Scale was associated with higher all-cause mortality after LAAO, with zero recurrent ischemic events.
Synapse has enriched 10 related papers. Consider them for comparative context: